To analyze the efficacy of beraprost and sildenafil for treatment of pulmonary hypertension in children with left to right shunt. analyze the efficacy and side effects.
Eligibility criteria: Inclusion: 1. children aged 1-17 years with left to right shunt, diagnosed as pulmonary hypertension. 2. free from chronic pulmonary disease 3. never performed any cardiac surgical 4. never got any treatment for PH 5. agree to enroll in this study. Exclusion 1\. suffer from portal hypertension, HIV and connective tissue disease 2. under interferon therapy. Outcome measure: Pulmonary artery pressure
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
40
1 mcg /kgbw daily, divided in three dosages orally for 12 weeks
0.4 mg/kgbw each time, 4 times in a day orally for 12 weeks
Dr. Soetomo General Hospital
Surabaya, East Java, Indonesia
Efficacy of Beraprost, Sildenafil and comparison between both drugs in lowering pulmonary arterial pressure
Measuring mPAP (pre-post therapy) via echocardiography before and after consuming sildenafil or beraprost
Time frame: 12 weeks
Emergent Adverse Events
adverse event reported by patients and during weekly examination after consuming Beraprost or Sildenafil: hypotension, dizzy, headache, flushing, bleeding
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.